UniQure Downsizes Gene Therapy Ambitions, Pins Hopes On Huntington’s Data
Cutbacks to its workforce and early pipeline could help UniQure focus on core assets – but upcoming readouts to Huntington’s disease gene therapy will be key for investors.
Cutbacks to its workforce and early pipeline could help UniQure focus on core assets – but upcoming readouts to Huntington’s disease gene therapy will be key for investors.